2 completed, 1 not yet recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Metastatic (Stage IV) Melanoma: new trials by email Literature Review of Metastatic (Stage IV) Melanoma trials Research Report on Metastatic (Stage IV) Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant - Metastatic (Stage IV) Melanoma | Phase 2 | Not yet recruiting | UNICANCER | 51 | 2026-09-18 | 2026-08-03 |
| RTA 408 Capsules in Patients With Melanoma - REVEAL Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg) - Melanoma, Unresectable (Stage III) Melanoma | Phase 1 / Phase 2 | Completed | Biogen | 41 | 2014-10-31 | 2025-06-04 |
| Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy blood sample - Metastatic (Stage IV) Melanoma | Not applicable | Completed | Centre Hospitalier Universitaire de Nice | 22 | 2014-05-01 | 2026-03-31 |
Melanoma (3) · Neoplasm Metastasis (3)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neoplastic Processes (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin Neoplasms (3) · Skin and Connective Tissue Diseases (3)
Blood Specimen Collection (1) · Fulvestrant (1) · Ipilimumab (1) · Nivolumab (1) · ORF 50 transactivator (1) · omaveloxolone (1)
Biogen (1) · Centre Hospitalier Universitaire de Nice (1) · UNICANCER (1)
France (2) · United States (1)
2025 (1)